Stephen Marley Launches Plant-Based CBD Personal Care Line

Dec.14.2022
Stephen Marley Launches Plant-Based CBD Personal Care Line
Stephen Marley releases plant-based Kx Family Care, featuring CBD-infused Hair and Beard Oil, Pain Relief Balm, and more.

On Monday, Grammy-winning artist Stephen Marley launched a product line called Kx Family Care, which is a plant-based CBD personal care collection that utilizes the benefits of cannabis and other herbs traditionally used in Jamaica.


The debut series features limited holiday packages containing two products: a versatile hair and beard oil, and a pain relief balm both infused with full spectrum CBD oil, known for its anti-inflammatory, antibacterial, and antioxidant properties.


These two products also contain sunflower oil, vitamin E, and linoleic acid, which have antioxidants that help protect the skin from free radical damage and maintain its natural barrier. They also contain black seed oil, sapodilla fruit extracts, and star apple, which are widely used in Jamaican culture for their regenerative properties.


For example, Jamaican black castor oil comes from the seeds of the Nigella sativa plant, which is rich in antioxidants and offers various health benefits.


Kx Family Care is a natural progression for me, due to my passion for the cannabis plant and its various uses," said founder Stephen Marley. "This brand is authentic in every way, from the natural infusion of Jamaican plants in our products, to the eco-friendly wood and glass packaging we use. Our goal is centered on family, natural health, sustainability, and respect for the many uses of the cannabis plant.


Kx Family Care is the multi-generational personal-care product branch of Kaya Lifestyle, owned and operated by Marley. Kaya Lifestyle also hosts Kaya Fest, a music and education cannabis advocacy festival.


Marley joined the CEO and co-founder Shelly O'Neill to spend three years researching and developing a plant-based, multipurpose product designed specifically for busy families. Marley believes that marijuana is just like any other useful herb. "Marijuana is an herb, like mint or sage, that can cure many diseases and provide spiritual enlightenment," Marley told the cultural magazine in 2018.


The idea for Kx Family Care arose while O'Neill and Marley were working together at Kaya Fest, a world music festival organized by Marley to promote education surrounding the various uses of the cannabis plant. The term "Kaya" is a Jamaican slang word for herb, derived from the Caribbean English word "kayakiit," meaning a type of herb.


Experience Marley's cannabis products firsthand: Kx Family Care's pop-up store will be opening on specific dates during Stephen Marley's upcoming Old Soul Tour - Unplugged 2023.


We are pleased to introduce the first all-natural, cannabis-based personal care brand that is safe and effective for the entire family," said founder Stephen Marley. "We look forward to giving our customers a firsthand experience of the Kx Family Care pop-up store at the specific date of The Old Soul Tour - Unplugged in 2023.


The company stated that the US Food and Drug Administration (FDA) does not require basic safety testing on ingredients in personal care products. These products often contain toxic ingredients that can harm the skin and hair.


The company also maintains its commitment to the environment in its packaging.


Kx Family Care aims to utilize eco-friendly materials including hemp plastic to showcase the various uses of the cannabis plant and reduce plastic waste, according to its website. Inspired by Jamaica's nickname as the "land of wood and water," the company captures the essence by using biodegradable wood and glass in its packaging. Kx also spreads love by supporting different charitable organizations every quarter with a portion of its sales revenue.


Several siblings and family members of Marley have ventured into the CBD or cannabis business, including Ziggy and Damian.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03